MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt flag Egypt · Delayed Price · Currency is EGP
766.83
-8.38 (-1.08%)
At close: Aug 25, 2026

MINAPHARM Pharmaceuticals Cash Flow Statement

Millions EGP. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
360.4840.22157.07-31.99612.66466.41
Depreciation & Amortization
415.36380.18284.71192.23132.8685.99
Loss (Gain) From Sale of Assets
0.160.155.670.17--0.46
Provision & Write-off of Bad Debts
22.85204012.64-2.67-8.91
Other Operating Activities
169.9118.86158.86-88.9281.6490.93
Change in Accounts Receivable
-234.83279.66-271.35-147.28-168.51-22.41
Change in Inventory
-386.8-277.91-180.96-226.43-171.08-83.29
Change in Accounts Payable
-95.95-58.45265.839.82265.15-91.57
Change in Other Net Operating Assets
72.0862.11-238.28352.1-188.28-229.4
Operating Cash Flow
323.25464.81221.51102.34561.77207.28
Operating Cash Flow Growth
1653.10%109.83%116.44%-81.78%171.03%-52.58%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-858.75-787.8-918.96-1,395-1,160-387.87
Sale of Property, Plant & Equipment
-0--0.17-0.76
Sale (Purchase) of Intangibles
-3.94-3.94-0.09-10.65-2.03-1.82
Investment in Securities
5-----
Other Investing Activities
100.8963.8845.2600-0.01
Investing Cash Flow
-756.81-727.85-573.79-1,405-1,162-388.94

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-5,9622,4961,020494.8-
Long-Term Debt Issued
-909.351,334459.34636.62425.73
Total Debt Issued
7,0186,8713,8301,4791,131425.73
Short-Term Debt Repaid
--6,388-2,227---205.3
Long-Term Debt Repaid
--1,870-292.72-128.71-12.15-11.86
Total Debt Repaid
-8,217-8,258-2,520-128.71-12.15-217.16
Net Debt Issued (Repaid)
-1,199-1,3861,3101,3501,119208.57
Issuance of Common Stock
2,1732,173----
Repurchase of Common Stock
-----69.63-
Common Dividends Paid
-62.1-60.31-40.16-53.87-57.79-49.8
Other Financing Activities
-30.75-27.4746.35-0.082.31-3.2
Financing Cash Flow
881.37699.341,3161,296994.16155.57

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
437.3633.065.49230.86317.88-13.97
Miscellaneous Cash Flow Adjustments
------1.5
Net Cash Flow
885.17469.35969.43224.34711.56-41.56

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-535.5-322.99-697.45-1,292-598.45-180.6
Free Cash Flow Growth
------
Free Cash Flow Margin
-8.05%-5.02%-12.46%-33.21%-16.53%-6.01%
Free Cash Flow Per Share
-48.40-29.19-63.04-116.81-52.16-14.69
Levered Free Cash Flow
-623.92-183.62-362.97-1,317-622.61-139.42
Unlevered Free Cash Flow
-187.55284.288.07-1,158-583.75-108.9

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
649.41748.64593.68254.4662.1748.84
Cash Income Tax Paid
-76.8426.07132.95182.39154.77
Change in Working Capital
-645.515.4-424.7918.21-262.72-426.67